Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2014760 | 0.98 | EPHX1 (0.59) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| SCHEMBL5320954 | 0.88 | EPHX1 (0.47) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| SCHEMBL14222420 | 0.88 | EPHX1 (0.47) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| SCHEMBL1778461 | 0.88 | EPHX1 (0.47) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL17560408 | 0.86 | EPHX1 (0.45) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL17560597 | 0.86 | EPHX1 (0.45) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL17560406 | 0.86 | EPHX1 (0.45) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| SCHEMBL8464579 | 0.84 | EPHX1 (0.46) | EPHX1POLBEPHX2TSHRNPSR1 | |
| SCHEMBL2050427 | 0.84 | — | — | |
| Toluene SCHEMBL28242089 | 0.83 | EPHX1 (0.44) | EPHX1POLBHTR4SMYD3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714499-A2 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-20250230129-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) | 2025-07-17 | — | — | US | disclosed |
| EP-4497754-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-01-29 | — | — | EP | disclosed |
| WO-2024054512-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023179659-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | 江苏恩华药业股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| WO-2023280237-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | 海创药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-11377453-B2 | Crystal of compound having JAK-inhibiting activity | NIPPON SHINYAKU CO., LTD. (JP) | 2022-07-05 | — | — | US | disclosed |
| US-20210017191-A1 | CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY | NIPPON SHINYAKU CO., LTD. (JP) | 2021-01-21 | — | — | US | disclosed |
| EP-3424930-B1 | CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY | NIPPON SHINYAKU CO LTD (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-10822350-B2 | Crystal of compound having JAK-inhibiting activity | NIPPON SHINYAKU CO., LTD. (JP) | 2020-11-03 | — | — | US | disclosed |
| WO-2006052889-A2 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | THERAVANCE, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | THERAVANCE, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20050197333-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS PHARMA LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005062882-A2 | RIFAMYCIN ANALOGS AND USES THEREOF | ACTIVBIOTICS, INC (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005020894-A2 | RIFAMYCIN ANALOGS AND USES THEREOF | ACTIVBIOTICS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043298-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS PHARMA LLC | 2005-02-24 | — | — | US | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| EP-0467325-A2 | Carbostyril derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| US-5082847-A | Antiarrhythmia | SYNTEX (U.S.A.) INC. (US) | 1992-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230129-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | ADCYAP1R1, PAICS, AGPS | EPHX1 2964/4885POLB 299/4885GNAI3 1251/4885 |
| US-11377453-B2 | Crystal of compound having JAK-inhibiting activity | JAK1, JAK2, JAK3 | EPHX1 3298/4885POLB 2747/4885GNAI3 512/4885 |
| US-20050197333-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, AADAC | EPHX1 2641/4885POLB 1001/4885GNAI3 3315/4885 |
| US-20050043298-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, AADAC | EPHX1 2641/4885POLB 1001/4885GNAI3 3315/4885 |
| US-10822350-B2 | Crystal of compound having JAK-inhibiting activity | JAK1, JAK2, JAK3 | EPHX1 3298/4885POLB 2747/4885GNAI3 512/4885 |
| US-20210017191-A1 | CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY | JAK1, JAK2, JAK3 | EPHX1 3298/4885POLB 2747/4885GNAI3 512/4885 |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | GIPR, GPR4, GPR119 | EPHX1 754/4885POLB 3377/4885GNAI3 306/4885 |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | HTR4, HTR5A, HTR2C | EPHX1 1542/4885POLB 3514/4885GNAI3 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.